Scarica l'app Stockscreener
3.5198
5.45%
0.2198
Nkarta Inc Borsa (NKTX) Ultime notizie
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to earnings forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy - Stock Titan
Nkarta Inc (NKTX) Institutional Confidence - TradingKey
TD Cowen initiates Nkarta stock with buy rating on NK cell therapy - Investing.com
TD Cowen Initiates Nkarta(NKTX.US) With Buy Rating - Moomoo
TD Cowen Initiates Nkarta at Buy - Moomoo
Nkarta (NKTX) CEO reports 1,776-share tax-related sale, holds 390,247 shares - Stock Titan
Nkarta (NKTX) Stock Price, News & Analysis - MarketBeat
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NKTX Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical ProgressEarnings Quality Score - newsline.com
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
These healthcare stocks are combining strong gains with reasonable prices (XLV:NYSEARCA) - Seeking Alpha
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss and Promising Pipeline Updates Spark 12% Rally - newsline.com
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay - TipRanks
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay - Stock Titan
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital - Stock Titan
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027 - Stock Titan
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant - Stock Titan
Nkarta (NKTX) director receives stock options on 37,000 common shares - Stock Titan
Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds - Stock Titan
Nkarta director granted options on 37,000 shares | NKTX Insider Trading - Stock Titan
Nkarta (NKTX) director awarded stock options for 37,000 shares at $2.46 - Stock Titan
Nkarta (NKTX) director Angela Thedinga awarded 37,000 stock options - Stock Titan
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - newsline.com
Nkarta Inc. (NKTX) Edges Lower: Assessing Support and Resistance in a Volatile Biotech MarketDefined Outcome ETF - newsline.com
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans - Moomoo
Nkarta Inc. (NKTX) Edges Higher on Above-Average Volume, Nears Key ResistanceDealer Positioning - newsline.com
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressTech Earnings Analysis - The Legal Advocate
NKTXNkarta Inc Short Interest - Finviz
NKTX Q1 2026 Earnings: Narrower-than-expected loss lifts sharesEarnings Quality Analysis - newsline.com
Nkarta Inc. (NKTX) Rallies 3.45% as Buyers Defend Key Support LevelSign of Strength - thelegaladvocate.com
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care - Finimize
Nkarta Inc. (NKTX) Advances 4.25% as Biotech Sector Momentum BuildsMESA MA - thelegaladvocate.com
Nkarta Inc. (NKTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances Pipeline - The Legal Advocate
1.53%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):